Acorda Therapeutics ACOR
-
New Morningstar Analyst Report for Biogen Idec Inc
… potential, and we forecast peak sales beyond $3.5 billion. We're also optimistic about the potential of Fampyra; Acorda ACOR received FDA approval for the novel MS drug (marketed as Ampyra in the United States) in 2010, and we think the drug …
-
Catalyst Deserves The Attention
By Veziris Ventures : Biotechnology companies focused on developing drugs targeting orphan disease indications have recently been some of the best performers in Biotech. The success of companies with approved and marketed orphan drug products such as Alexion Pharmaceuticals ( ALXN ), Vertex ...
-
Acorda Therapeutics ([[ ACOR ]] +11.2%) rises for a second day after AMPYRA shows promise for post-stroke deficit patients. Heard on the conference call: 1) "What got us here [is] an adherence to ...
Acorda Therapeutics ( ACOR +11.2% ) rises for a second day after AMPYRA shows promise for post-stroke deficit patients. Heard on the conference call …
-
Midday top 10 gainers: [[UNXL]] +16%. [[CNIT]] +15%. [[ANEN]] +15%. [[CHCI]] +14%. [[SYNM]] +13%. [[PNFP]] +12%. [[EVC]] +12%. [[ENPH]] +11%. [[NCQ]] +11%. [[ ACOR ]] +11%. Midday top 10 losers: ...
… UNXL +16% . CNIT +15% . ANEN +15% . CHCI +14% . SYNM +13% . PNFP +12% . EVC +12% . ENPH +11% . NCQ +11% . ACOR +11% . Midday top 10 losers: JAXB -33% . KEYN -15% . SRPT -12% . CPGI -10% . GENE -10% . TRIT -9% . CCXI -9 …
-
Cramer's Mad Money - The Fight Over Sprint Is Just Beginning (4/15/13)
By SA Editor Miriam Metzinger : Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Monday April 15. A Fight That Is Just Beginning: Dish Network ( DISH ), Sprint Nextel ( S ), Softbank ( SFTBF.PK ) Dish Network ( DISH ) announced a takeover bid for Sprint ( S ), and ...
-
Acorda Therapeutics' CEO Hosts Revision of the Study Findings of AMPYRA Tablets Conference (Transcript)
Acorda Therapeutics , Inc. ( ACOR ) April 15, 2013 8:30 am ET ..... for holding. Welcome to the Acorda Therapeutics Conference Call. [Operator ..... seekingalpha.com/article/1343341- acorda - therapeutics -inc-special-call?source …
-
Midday top 10 gainers: [[MKTAY]] +143%. [[CNIT]] +21%. [[GENE]] +21%. [[THRX]] +18%. [[MCOX]] +17%. [[SGRP]] +14%. [[S]] +13%. [[STXS]] +10%. [[ ACOR ]] +9%. [[LIFE]] +8%. Midday top 10 losers: ...
… top 10 gainers: MKTAY +143% . CNIT +21% . GENE +21% . THRX +18% . MCOX +17% . SGRP +14% . S +13% . STXS +10% . ACOR +9% . LIFE +8% . Midday top 10 losers: UNTK -48% . GSS -19% . ASM -18% . DSCO -17% . HXM -16% . XPL -16% . NGD …
-
Acorda : A Biotech Company To Consider
By Northrop Puckett : Acorda Therapeutics ( ACOR ) is a bio-pharmaceutical company that engages in the identification ..... debt, with a long term debt-to-equity ratio of .01. Acorda also has a profit margin of 50% and sports a return on equity …
-
Alkermes Still Not Getting Full Credit For Its Pipeline
By Stephen Simpson : Biotech is a strange world, one where investors often seem to prefer stories that are relatively weak on sales, earnings, and actual data. Maybe that makes a certain amount of sense - in the absence of data, investors are free to dream about blockbuster drugs and multi-baggers.
-
Acorda Therapeutics' CEO Presents at Citi 2013 Global Healthcare Conference (Transcript)
Acorda Therapeutics , Inc. ( ACOR ) February 27, 2013 1:30 pm ..... the Chief Executive Officer at Acorda . So, Ron, thanks so much for ..... seekingalpha.com/article/1231871- acorda - therapeutics -inc-presents-at-citi …